Testosterone Testing for Women: What Labs to Order and How to Read Your Results

Why Standard Reference Ranges Don't Tell the Whole Story

Your laboratory report shows testosterone firmly within "normal" range. The symptoms persist—low libido, stubborn body composition changes, energy that never returns to baseline. This is the gap between population averages and individual optimization, between what laboratories label normal and what your body requires to function optimally.

Women searching for information on testosterone in women levels typically arrive with symptoms, questions about treatment eligibility, or results that don't align with how they feel. The standard reference range—a statistical construct from population sampling—offers a starting point, rarely the complete picture.

The Project Rx approach to hormone testing begins with precision: the right assays, ordered at optimal timing, interpreted within the context of symptoms, life stage, and treatment goals. This matters because testosterone is a Schedule III controlled substance requiring documented medical justification, appropriate laboratory findings, and ongoing physician oversight. Understanding which tests inform clinical decisions is where measurement becomes meaning.

The Tests That Actually Matter: Beyond Total Testosterone

Total Testosterone: The Methodology Question

Most commercial laboratories measure testosterone using immunoassays—antibody-based tests designed for higher concentrations in male physiology. In women, where circulating testosterone typically ranges from 15 to 70 ng/dL, these assays lack sensitivity to reliably detect and quantify such low levels. Immunoassays can report false negatives or introduce significant measurement error when testosterone falls below 50 ng/dL.

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) represents the gold standard for measuring female testosterone. This method physically separates and identifies testosterone molecules rather than relying on antibody recognition, providing accurate quantification even at very low concentrations. When providers order testosterone testing for women, assay methodology matters—not all testosterone tests provide reliable results, and the distinction determines whether your numbers can be trusted.

Free Testosterone: Bioavailability, Not Just Quantity

Total testosterone measures all circulating testosterone: the portion bound tightly to sex hormone-binding globulin (SHBG), the portion loosely attached to albumin, and the small fraction circulating unbound. Only the latter two—collectively termed bioavailable testosterone—interact with androgen receptors to produce physiological effects.

Free testosterone can be measured directly (an expensive, technically challenging assay rarely used clinically) or calculated using total testosterone, SHBG, and albumin values. Calculation methods like the Vermeulen equation provide reliable estimates when high-quality LC-MS/MS total testosterone values are used.

This matters because two women with identical total testosterone can have dramatically different free testosterone depending on SHBG concentrations. One may be symptomatic despite seemingly adequate total levels; the other asymptomatic with lower totals but more favorable binding protein ratios.

SHBG: The Binding Protein That Determines Availability

Sex hormone-binding globulin binds testosterone and estradiol with high affinity, effectively sequestering these hormones from tissue interaction. SHBG levels vary widely based on estrogen status, thyroid function, insulin sensitivity, liver health, and genetics.

High SHBG—common with oral estrogen therapy, hyperthyroidism, or certain genetic variants—reduces free testosterone even when total levels appear adequate. Low SHBG, often seen with insulin resistance or polycystic ovary syndrome (PCOS), can elevate free testosterone despite modest total levels.

Any comprehensive androgen assessment must include SHBG. Testing total testosterone alone is insufficient for clinical decision-making.

Albumin: Completing the Bioavailability Calculation

Albumin, the most abundant protein in plasma, binds testosterone with low affinity. This loosely bound fraction can dissociate and enter tissues, making it part of the bioavailable pool. Most laboratories measure albumin as part of routine chemistry panels, and this value feeds into free testosterone calculations.

While albumin varies less dramatically than SHBG, it still contributes to calculated free testosterone accuracy, particularly in women with liver disease, malnutrition, or inflammatory conditions that suppress albumin synthesis.

Understanding Your Numbers: Reference Ranges vs. Optimal Ranges

Reference ranges printed beside your results represent the statistically normal distribution within the tested population—typically the middle 95th percentile. For total testosterone measured by LC-MS/MS, laboratories commonly report:

• Premenopausal women: 15–70 ng/dL
• Postmenopausal women: <20 ng/dL (often with upper limits around 40 ng/dL)

These numbers describe what is, not necessarily what is optimal for individual function. They are population averages from diverse cohorts with varying symptom burdens, not thresholds for clinical intervention.

Research examining androgen deficiency suggests that total testosterone levels below 25 ng/dL in women under 50 and below 20 ng/dL in women over 50 may correlate with symptoms of androgen insufficiency—diminished sexual desire, reduced energy, changes in mood and cognitive function. These are not diagnostic cutoffs but levels at which symptoms become more prevalent and treatment consideration becomes clinically reasonable.

Free testosterone reference ranges vary widely depending on calculation method and laboratory. Typical ranges for premenopausal women fall between 0.3 and 1.9 ng/dL by equilibrium dialysis, though calculated free testosterone may report different units and ranges.

Symptom correlation matters more than arbitrary cutoffs. A woman with total testosterone of 35 ng/dL—well within reference range—may still experience symptoms if her SHBG is elevated, her free testosterone is at the lower end of normal, and her historical baseline was higher before surgical menopause or perimenopause. Conversely, a woman with testosterone at 18 ng/dL may be asymptomatic if her physiology has adapted.

Providers evaluating testosterone in women levels interpret results within full clinical context, not against a single number on a printout.

When and How to Test: Timing, Preparation, and Method Matter

Time of Day

Testosterone exhibits diurnal variation in men, with peak levels in early morning and decline throughout the day. In women, this pattern is far less pronounced—female testosterone secretion shows minimal circadian rhythm compared to male physiology.

Nevertheless, for consistency and to control for subtle variation, early morning testing (ideally between 7:00 and 10:00 a.m.) is preferred. This standardization allows for more meaningful comparison if testing is repeated, reducing noise introduced by timing differences.

Menstrual Cycle Timing

In women with regular menstrual cycles, testosterone levels fluctuate slightly across the cycle, with a small peak around ovulation. To minimize variability and establish a consistent baseline, testing during the follicular phase (days 3–5 of the menstrual cycle, where day 1 is the first day of menstrual bleeding) is recommended.

For postmenopausal women or those without regular cycles (due to hormonal contraception, hysterectomy, or other factors), cycle timing is irrelevant, and testing can occur anytime.

Fasting vs. Non-Fasting

Research shows that fasting status has minimal impact on testosterone levels in women, unlike lipid panels where fasting significantly affects results.

While fasting is not strictly necessary for testosterone measurement, many women undergo comprehensive metabolic panels or lipid testing simultaneously, which do require fasting. For practical purposes, a fasting morning draw simplifies logistics and aligns with other common lab requirements.

Avoiding Confounding Variables

Several factors can artificially suppress or elevate testosterone levels:

• Oral contraceptives increase SHBG substantially, lowering free testosterone even if total levels remain within range
• Exogenous DHEA supplementation can elevate measured testosterone
• Biotin supplementation (often in hair/skin/nail vitamins) can interfere with immunoassay results, though LC-MS/MS is less affected
• Acute illness or stress can transiently alter hormone levels

Ideally, testing should occur during stable health, with awareness of medications and supplements that influence androgen metabolism.

Reading Results in Context: What Providers Look For

Laboratory values represent data points. The clinical picture requires interpretation.

Symptom Burden

Providers assess the constellation of symptoms potentially attributable to low testosterone:

• Persistent reduction in libido unrelated to relationship factors or medications
• Decreased energy and motivation despite adequate sleep and thyroid function
• Changes in body composition, particularly difficulty maintaining muscle mass
• Subtle shifts in mood, cognitive clarity, or sense of vitality

These symptoms are nonspecific—they overlap with thyroid disorders, iron deficiency, vitamin D insufficiency, perimenopause-related estrogen decline, depression, and chronic stress. Testosterone testing becomes clinically meaningful when symptoms align with potentially low androgen levels and other common causes have been evaluated.

Life Stage

The clinical significance of a given testosterone level shifts with reproductive status:

• Reproductive-age women with regular cycles and no surgical history rarely develop primary androgen deficiency unless affected by conditions like PCOS (where androgens are often elevated) or premature ovarian insufficiency
• Perimenopausal women may experience declines in testosterone alongside estradiol and progesterone fluctuations
• Postmenopausal women have physiologically lower testosterone, with production shifting primarily to the adrenal glands and peripheral conversion
• Surgically menopausal women (bilateral oophorectomy) lose a major source of testosterone production abruptly, often experiencing more pronounced symptoms

A total testosterone of 18 ng/dL carries different clinical weight for a 32-year-old with intact ovaries than for a 58-year-old a decade past menopause.

The Broader Hormonal Landscape

Testosterone does not exist in isolation. Providers review concurrent hormone levels:

• Estradiol and progesterone: In perimenopausal and postmenopausal women, estrogen deficiency often drives symptoms attributed to testosterone; estradiol replacement and progesterone therapy may address libido, energy, and mood concerns without androgen intervention
• Thyroid hormones: Hypothyroidism mimics low testosterone symptoms and elevates SHBG
• Cortisol: Chronic stress and HPA axis dysregulation suppress sex hormone production
• Prolactin: Hyperprolactinemia suppresses both testosterone and estrogen

Comprehensive evaluation ensures that androgen therapy targets actual androgen deficiency, not undiagnosed thyroid disease or untreated estrogen insufficiency.

Longitudinal Trends

A single testosterone measurement provides a snapshot. Serial testing over time reveals patterns: progressive decline, stability, or fluctuation. Historical data allows providers to contextualize current results against an individual's baseline rather than relying solely on population norms.

Not everyone qualifies for testosterone therapy. Eligibility is determined by licensed providers based on individual medical evaluation, including symptoms, laboratory findings, medical history, contraindications, and clinical judgment.

Common Testing Pitfalls and How to Avoid Them

Using Unreliable Assays

The most expensive test is the one that provides an inaccurate answer that misleads clinical decisions. Immunoassays marketed for convenience or lower cost cannot reliably measure testosterone in the female range. Insist on LC-MS/MS methodology for total testosterone, and confirm that your laboratory specifies the assay type on the report.

Testing Without Symptom Correlation

Laboratory values detached from clinical symptoms invite "lab chasing"—the pursuit of numerical optimization absent functional impairment. Testosterone testing is not a screening test for asymptomatic women. It becomes clinically relevant when specific symptoms prompt investigation and potentially support treatment consideration.

Misinterpreting SHBG

A woman with total testosterone at 40 ng/dL and SHBG at 120 nmol/L has substantially less bioavailable testosterone than a woman with the same total testosterone and SHBG at 30 nmol/L. Evaluating total testosterone without SHBG can obscure true androgen availability, leading to missed deficiency or inappropriate reassurance.

Ignoring Other Causes of Symptoms

Fatigue, low libido, and difficulty with weight are not specific to testosterone deficiency. Before attributing symptoms to low androgens, comprehensive evaluation should address:

• Thyroid function (TSH, free T4, free T3)
• Iron status (ferritin, CBC)
• Vitamin D levels
• Sleep quality and sleep disorders
• Psychological factors (depression, anxiety, relationship stressors)
• Medications with sexual or energy-related side effects (SSRIs, beta-blockers, antihypertensives)

Precision care requires ruling in the correct diagnosis, not simply pursuing the most convenient one.

Next Steps: From Results to Treatment Decisions

When laboratory findings and symptom burden suggest androgen deficiency, the pathway from testing to treatment involves several stages:

Provider Review

Licensed physicians review all laboratory results alongside your medical history, current medications, symptom timeline, and treatment goals. This review determines whether you meet clinical criteria for testosterone therapy and whether potential benefits outweigh risks for your individual situation.

Testosterone therapy for women remains an area of evolving clinical practice. While research supports efficacy for sexual desire concerns in postmenopausal women, particularly those with surgical menopause, not all symptoms or patient populations have robust evidence. Providers weigh the strength of evidence, symptom severity, the adequacy of trials with other interventions (such as estrogen or progesterone optimization), and individual risk factors.

Treatment Planning (If Qualified)

If you qualify for therapy, your provider designs a protocol tailored to your physiology:

• Topical formulations (creams or gels) allow for flexible dosing and steady absorption
• Troches (sublingual lozenges) provide an alternative delivery route

Compounded medications are not reviewed by the FDA for safety or efficacy. They represent customized alternatives when clinically appropriate, formulated by specialized pharmacies to meet individual patient needs under physician prescription.

Dosing begins conservatively, with the goal of alleviating symptoms while minimizing potential side effects such as acne, hair growth changes, or voice deepening. These adverse effects are dose-dependent and more common with excessive dosing or non-physiologic testosterone levels.

Monitoring Schedule

Ongoing medical oversight is required. Typical monitoring includes:

• Follow-up labs at 6–12 weeks after initiation to assess testosterone levels on therapy and adjust dosing
• Symptom reassessment to evaluate treatment response
• Periodic monitoring (every 6–12 months) of testosterone, lipid panel, liver function, and hematocrit

Testosterone therapy is not a one-time prescription but an ongoing partnership between patient and provider, adjusted iteratively based on response and laboratory feedback.

Potential side effects exist, and prescription decisions are made solely by licensed medical professionals. Treatment outcomes vary by individual. Some women experience meaningful improvement in libido, energy, and body composition; others notice minimal benefit or develop side effects that prompt discontinuation.

Testing as the First Step in Precision Care

Testosterone testing for women, when done with methodological rigor and clinical context, transforms from a simple blood draw into a meaningful data point within a broader evaluative process. It is neither a screening tool for the asymptomatic nor a diagnostic endpoint in isolation. Rather, it serves as one thread in comprehensive hormone assessment—informative when woven together with symptoms, life stage, concurrent hormone levels, and longitudinal trends.

Reference ranges printed on laboratory reports offer population statistics, not individual optimization thresholds. The distinction between normal and optimal, between measurement and meaning, requires physician interpretation anchored in both evidence and clinical experience.

The Project Rx approach is rooted in this precision: data-driven, individualized, medically supervised. For those seeking answers beyond reference ranges, the pathway begins not with assumption but with assessment—laboratories that measure accurately, providers who interpret thoughtfully, and protocols designed around the individual rather than the average.

Eligibility for therapy is never guaranteed by a laboratory value alone. It emerges from the integration of objective findings with subjective experience, always determined by licensed providers based on comprehensive medical evaluation.

FAQ

What is a normal testosterone level for women?

Reference ranges for total testosterone in women vary by age and laboratory methodology. Using LC-MS/MS (the most accurate assay), typical ranges are approximately 15–70 ng/dL for premenopausal women and often below 20–40 ng/dL for postmenopausal women. However, "normal" reflects population averages, not necessarily optimal levels for individual function. Symptom correlation and clinical context matter more than a single reference range.

What is the difference between free and total testosterone?

Total testosterone measures all circulating testosterone, including hormone bound to SHBG (sex hormone-binding globulin), loosely bound to albumin, and unbound (free). Free testosterone refers only to the unbound fraction, while bioavailable testosterone includes both free and albumin-bound hormone. Only bioavailable testosterone interacts with androgen receptors to produce physiological effects, making free testosterone a more clinically relevant marker than total testosterone alone.

Do I need to fast before a testosterone test?

Research indicates that fasting has minimal impact on testosterone in women levels, unlike tests such as lipid panels or glucose. However, testosterone testing is often performed alongside other labs that do require fasting. A fasting morning draw is generally recommended for convenience and to standardize conditions if repeat testing is needed.

When during my cycle should I test testosterone?

For women with regular menstrual cycles, testing during the follicular phase (days 3–5, where day 1 is the first day of bleeding) reduces variability and provides a consistent baseline. Testosterone peaks slightly around ovulation, so early-cycle testing minimizes this fluctuation. For postmenopausal women or those without cycles, timing is not relevant, and testing can occur anytime.

Why does SHBG matter for testosterone testing?

SHBG binds testosterone tightly, making it unavailable for tissue interaction. Two women with identical total testosterone can have very different free (bioavailable) testosterone depending on SHBG levels. High SHBG—common with oral estrogen, hyperthyroidism, or genetics—reduces free testosterone despite normal total levels. Low SHBG (often seen with insulin resistance) can elevate free testosterone. Testing SHBG is essential for interpreting total testosterone results accurately.

Can I interpret my testosterone results on my own?

Laboratory results provide data, but clinical interpretation requires medical expertise. Testosterone in women levels must be assessed alongside symptoms, life stage, SHBG and albumin levels, other hormones (estradiol, thyroid, cortisol), and potential alternative diagnoses. Self-interpretation risks missing nuances such as assay methodology limitations, binding protein effects, or unrelated causes of symptoms. Licensed providers integrate all these factors to determine clinical significance and treatment eligibility.

What if my testosterone is 'normal' but I still have symptoms?

This scenario is common. "Normal" reference ranges represent population averages, not individual optimal thresholds. Your testosterone may have declined from a higher personal baseline, your SHBG may be elevated (reducing free testosterone despite adequate total levels), or your symptoms may stem from other causes—estrogen deficiency, thyroid dysfunction, iron or vitamin D insufficiency, stress, or medication side effects. Comprehensive evaluation by a provider is necessary to identify the actual source and appropriate treatment.

What type of testosterone test is most accurate for women?

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for measuring testosterone in women. Immunoassays—commonly used in many commercial labs—lack the sensitivity and accuracy needed for the low testosterone concentrations found in female physiology. LC-MS/MS physically separates and quantifies testosterone molecules, providing reliable results even at very low levels. Always confirm your laboratory uses LC-MS/MS methodology for testosterone testing.